By Ian Walker

 

LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Wednesday a phase III study of mepolizumab has met all major targets in patients with eosinophilic granulomatosis with polyangiitis, a rare disease characterized by inflammation in the walls of small blood vessels.

The key goal of treatment is to induce and maintain remission while reducing the use of corticosteroids and other immunosuppressive therapies, Glaxo said.

It plans to use the results to support regulatory applications, which are expected in 2017.

 

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

 

(END) Dow Jones Newswires

November 23, 2016 02:41 ET (07:41 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.